Companies / ACR

ACRUX LIMITED

ASX:ACRPharmaceuticals, Biotechnology & Life Sciences
523.9M shares on issueASX (delayed) · as of 28 July 2026$0.011price · delayed$6.3Mmarket cap · indicative
F
Dilution grade

Runway under 2 quarters; share count grew 80% in 24 months; options/rights overhang 64% of shares

Cash runway0.5 quarters of funding
Share-count growth (24m)80.2%
Raise cadence (24m)2 cash raises
Options & rights overhang64.0% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

ACRUX LIMITED's ordinary share count grew 80.2% between March 2024 and July 2026 to 524M shares. The company raised capital twice in that period for total disclosed proceeds of A$3.2M, most recently a A$1.6M placement in May 2026. Options and rights on issue could convert into 335M new shares, equal to 64.0% of the current share count, with the nearest expiry in February 2027; none are in the money. At the March 2026 quarter ACRUX reported A$437K in available cash, equivalent to 0.5 quarters of funding at its recent spending rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
64.0%
Max option dilution
0.0%
ITM option dilution
2
Raises · last 12 months
0.5 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 523.9M per ASX (delayed) (28 July 2026).
339.7M407.3M474.9MDec 24Sept 25July 26Cash raise · 6 May 2026Cash raise · 6 May 2026

Cash runway

0.5 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$437k available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
23 July 20262A · quoted issueACR : ORDINARY FULLY PAID523.9MAppendix 2A
25 June 20262A · quoted issueACR : ORDINARY FULLY PAID522.8MAppendix 2A
1 June 20262A · quoted issueACR : ORDINARY FULLY PAID514.5MAppendix 2A
1 June 20263H · cancellationACR : ORDINARY FULLY PAID513.3MAppendix 3H
1 June 20262A · quoted issueACR : ORDINARY FULLY PAID521.1MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

2 cash raises in the last 24 months · 2 in the last 12 months

$1.6M
Placement
6 May 2026 ACTIVE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

64.0%
Total overhang · of current shares
0.0%
In the money · at current price
335.3M
Potential new shares
Feb 2027
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
24 July 2026Ross DobinsonOther1.1M——3Y notice
2 June 2026Don BrumleyOther8.8M2.3M—3Y notice
2 June 2026Ross DobinsonOther4.9M——3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

23 July 2026Appendix 3Y Dobinson
23 July 2026Application for quotation of securities - ACR
21 July 2026Results of Meeting
25 June 2026Application for quotation of securities - ACR
14 June 2026Notice of Extraordinary General Meeting/Proxy Form
2 June 2026Appendix 3Y Oldham
1 June 2026Appendix 3Y Dobinson
1 June 2026Appendix 3Y Brumley
1 June 2026Application for quotation of securities - ACR
1 June 2026Notification of cessation of securities - ACR
1 June 2026Application for quotation of securities - ACR
29 May 2026$PUpdate - Licensing Lenzetto for Australia for AUD5.4m
27 May 2026$PAcrux licenses Lenzetto for Australian market for AUD5.4m
17 May 2026Cleansing Notice
17 May 2026Application for quotation of securities - ACR
13 May 2026$PCapital Gains Tax exemptions remain in place for Acrux
11 May 2026Proposed issue of securities - ACR
11 May 2026$PAcrux raises $1.6 million via Share Placement
6 May 2026$PTrading Halt
30 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.